Specifically, in a patient with metastatic HR-positive, HER2-negative breast cancer in whom a curative option is not available, the approach we describe could provide the information needed to ensure that a therapy that is well-tolerated and may be bringing benefit by slowing tumor growth is not abandoned. Here, ERBB2 is linked to breast cancer.